Aim immunotech announces publication of positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer

Chemokine-modulating ip chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic t lymphocytes chemoattraction and function

AIM Ratings Summary

AIM Quant Ranking